Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem

Fineline Cube Jul 14, 2026
Company Deals

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Fineline Cube Jul 14, 2026
Company Deals

GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures

Fineline Cube Jul 14, 2026
Company Deals

Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar

Fineline Cube Jul 14, 2026
Company Deals

Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements

Fineline Cube Jul 13, 2026
Policy / Regulatory

China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration

Fineline Cube Jul 14, 2026
Company Drug

Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases

Fineline Cube Jul 14, 2026
Company Drug

B&K Corporation Completes Patient Enrollment in Phase II Diabetic Foot Ulcer Trial for Pro-101-2 rhPDGF-BB Therapy

Fineline Cube Jul 14, 2026
Company Drug

J&J’s Rybrevant SC Formulation Approved by EC for NSCLC Treatment

Fineline Cube Apr 8, 2025

The European Commission (EC) has approved the subcutaneous (SC) formulation of Johnson & Johnson’s (J&J,...

Company Deals

TJ Biopharma Partners with Biogen on Felzartamab Phase III Studies in China

Fineline Cube Apr 8, 2025

China-based TJ Biopharma has entered into an agreement with US-based Biogen Inc. (NASDAQ: BIIB) to...

Company Drug

J&J’s Darzalex SC Formulation Approved for Newly Diagnosed Multiple Myeloma

Fineline Cube Apr 8, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received clearance from the European...

Policy / Regulatory

Shenzhen Unveils Comprehensive Policy Package to Boost Biopharma Innovation

Fineline Cube Apr 8, 2025

Shenzhen has launched an ambitious policy package, “Several Measures to Support Pharmaceuticals and Medical Devices...

Company Drug

AIM Vaccine’s Serum-Free Rabies Vaccine Accepted for Review by NMPA

Fineline Cube Apr 8, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) announced that its market filing for a serum-free...

Company Drug

SinoMab BioScience’s SM17 Shows Promising Results in Phase Ib Atopic Dermatitis Study

Fineline Cube Apr 8, 2025

Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced positive results from the Phase...

Company Drug

Luye Pharma’s Toludesvenlafaxine Approved for Marketing in Macau

Fineline Cube Apr 8, 2025

China-based Luye Pharma Group (HKG: 2186) announced that its extended-release depression treatment, toludesvenlafaxine (LY03005), has...

Company Drug

Shanxi Yanghe Medical Technology Faces Production Halt Over GMP Violation

Fineline Cube Apr 8, 2025

China’s National Drug Alliance Procurement Office has imposed manufacturing suspensions on Shanxi Yanghe Pharmaceutical Technology’s...

Company Drug

Hansoh Pharmaceutical Secures Dual NMPA Approvals for Oncology Pipeline Expansion

Fineline Cube Apr 8, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving dual clinical trial approvals...

Company Drug

Huadong Medicine’s DR30206 Approved for Clinical Trials in Gastrointestinal Tumors

Fineline Cube Apr 8, 2025

China-based Huadong Medicine Co., Ltd. (SHE: 000963) announced that it has received clinical trial approval...

Policy / Regulatory

Beijing Unveils Measures to Accelerate Innovative Drug Development and Regulatory Efficiency

Fineline Cube Apr 8, 2025

The Beijing Municipal Medical Insurance Bureau, in collaboration with seven other bureaus, has released the...

Company Deals

Novo Nordisk Partners with Tencent Healthcare for Weight Management Initiative in China

Fineline Cube Apr 8, 2025

In alignment with China’s “Weight Management Year” initiative, Denmark-based Novo Nordisk A/S (NYSE: NVO) has...

Company Deals

Siemens Set to Acquire Dotmatics for $5.1 Billion to Boost Life Sciences R&D

Fineline Cube Apr 8, 2025

German industrial giant Siemens AG (ETR: SIE) has announced plans to acquire US-based Dotmatics, a...

Company Deals

Lynmou Medical Secures Series A Funding for Endoscope Expansion

Fineline Cube Apr 8, 2025

Lynmou Medical, a Hangzhou-based provider of soft endoscope solutions, has reportedly secured “tens of millions”...

Company Drug

Phanes Therapeutics Gains CDE Approval for Peluntamig Phase II Trial in SCLC and NEC

Fineline Cube Apr 8, 2025

Sino-US biotech Phanes Therapeutics Inc. announced receiving approval from the Center for Drug Evaluation (CDE)...

Company Deals

Hengrui Pharmaceuticals Licenses SHR7280 to Merck for Assisted Reproduction

Fineline Cube Apr 8, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has entered into a licensing agreement with...

Company Drug

Suzhou Ribo Life Science Completes Enrollment for Phase IIa Study of FXI-Targeted siRNA Drug RBD4059

Fineline Cube Apr 8, 2025

China-based Suzhou Ribo Life Science Co., Ltd announced the completion of subject enrollment for the...

Company Drug

Nanjing King-Friend Bio’s Biosimilar Victoza Approved by FDA

Fineline Cube Apr 7, 2025

China-based Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (SHA: 603707) announced that its Abbreviated New Drug...

Company Drug

Bio-Sincerity Pharma-tech Gains NMPA Approval for BIOS-0618 in Obstructive Sleep Apnea

Fineline Cube Apr 7, 2025

Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) has secured clinical trial approval from China’s National...

Company Deals

Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline

Fineline Cube Apr 7, 2025

China-based Duality Biotherapeutics, Inc. (HKG: 9606) successfully debuted in Hong Kong after completing an initial...

Posts pagination

1 … 210 211 212 … 694

Recent updates

  • CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem
  • China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration
  • Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases
  • China’s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines
  • B&K Corporation Completes Patient Enrollment in Phase II Diabetic Foot Ulcer Trial for Pro-101-2 rhPDGF-BB Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

CR Pharmaceutical Commercial and Innovent Biologics Forge Strategic Partnership to Build Integrated Health Management Ecosystem

Policy / Regulatory

China’s State Council Unveils “15th Five-Year” National Health Plan with Strong Support for Innovative Therapeutics and AI Integration

Company Drug

Haisco Pharmaceutical Secures NMPA IND Acceptance for HSK60002 Tablets in Inflammatory Diseases

Policy / Regulatory

China’s NHSA Completes Preliminary Review of 2026 Medical Insurance Catalog with 91% Pass Rate for Basic Medicines

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.